1. Li L, Zhu X, Chen X, Gao J, Ding C et al (2022) Advances in targeted therapy for pulmonary arterial hypertension in children. Eur J Pediatr
2. Volibris Product Information https://www.ema.europa.eu/en/documents/product-information/volibris-epar-product-information_en.pdf. Accessed 12 Jan 2023
3. Ivy D, Beghetti M, Juaneda-Simian E et al (2020) A randomized study of safety and efficacy of two doses of ambrisentan to treat pulmonary arterial hypertension in pediatric patients aged 8 years up to 18 years. J Pediatr X 5:100055
4. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, ESC/ERS Scientific Document Group et al (2023) 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 61(1):2200879
5. Laffan S, Kohrs L, Kambara T, Rambo M, Jucker B et al (2019) Brain weight effect of ambrisentan in juvenile rats associated with breathing sounds, apnea and sustained hypoxemia. Presented at the 59th Teratology Society Annual Meeting, San Diego, CA